What’s inside
View ResearchDelve into how dupilumab dampens the mucosal type 2 response during acetylsalicylic acid (ASA) challenge in patients with NSAID-exacerbated respiratory disease (N-ERD). This study investigates the dynamics of nasal mediators and transcriptomic profiles in N-ERD patients before and after 24 weeks of dupilumab therapy. Results show a significant reduction in type 2 cytokines (TSLP, IL-5, CCL17, eotaxin-3) post-therapy, highlighting dupilumab’s potential in managing ASA-induced hypersensitivity reactions.
Dupilumab in N-ERD Patients
Dupilumab reduces type 2 mucosal response during acetylsalicylic acid challenge in N-ERD patients.
Dynamics of Nasal Mediators with Dupilumab
Study analyzes nasal mediators in N-ERD patients before and after dupilumab therapy during ASA challenge.
Type 2 Cytokine Reduction by Dupilumab
Dupilumab significantly reduces type 2 cytokines like TSLP and IL-5 during ASA provocation in N-ERD.
Transcriptomic Changes Post-Dupilumab Therapy
Dupilumab alters gene expression related to type 2 pathways and lipid metabolism during ASA challenge in N-ERD.
Clinical Improvements with Dupilumab in N-ERD
Dupilumab improves clinical symptoms and reduces polyp size and nasal inflammation in N-ERD patients.
Tolerance Development and Cytokine Patterns
Tolerance to ASA in N-ERD patients treated with dupilumab shows no specific cytokine pattern association.
.svg)
.jpg)
.webp)
